1. Singh BN. Amiodarone: historical development and pharmacologic profile. Am Heart J106:788, 1983
2.
2. Charlier R, Deltour G, Baudine A, et al. Pharmacology of amiodarone: an antianginal drug with a new biological profile. Arzneimittelforschung18:1408, 1968
3.
3. Singh BN, Vaughan Williams EM. The effect of amiodarone: a new anti-anginal drug, on cardiac muscle. Br J Pharmacol39:657, 1970
4.
4. Singh BN, Vaughan Williams EM. A third class of antiarrhythmic actions? Effects on atrial and ventricular intracellular potentials and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol39:675, 1970
5.
5. The CASCADE Investigators.The Cascade Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. Am J Cardiol72:280, 1983
6.
6. Singh BN. Implantable cardioverter defibrillators: not the ultimate gold standard for gauging therapy for ventricular tachycardia and fibrillation?Am J Cardiol73:1211, 1991
7.
7. Zipes DP. Implantable cardioverter-defibrillator: life-saver or device looking for a disease?Circulation91:2115, 1994
8.
8. Nademanee K, Singh BN, Hendrickson J, et al. Amiodarone in refractory life-threatening ventricular arrhythmias. Ann Intern Med98:57, 1983
9.
9. Weinberg BA, Miles WM, Klein LS, Bolander JE, et al. Five-year follow-up of 589 patients treated with amiodarone. Am Heart J125:109, 1993
10.
10. Singh SN, Gross-Fisher S, Fletcher RD, Singh BN, el al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmias. N Engl J Med33:77, 1995
11.
11. Middlekauff HR, Wiener I, Saxon LA, Stevenson WG. Low-dose amiodarone for atrial fibrillation: time for a prospective study?Ann Intern Med116:1017, 1992
12.
12. Chun S, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh B.Amiodarone is highly effective in maintaining NSR in refractory atrial fibrillation/flutter. Am J Cardiol76:47, 1995
13.
13. Doval HC, Nul DR, Vancelli HO, Elizari M, Randomizedtrial of low-dose amiodarone in severe congestive heart failure. Lancet344:493, 1994
15. Singh BN, Ahmed R. Class III antiarrhythmic drugs. Curr Opin Cardiol19:12, 1994
16.
16. Holnloser S, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia. Ann Intern Med121:529, 1994
17.
17. Nasir N, Swama US, Boahene KA, Doyle TK, Pacifico A.Therapy of sustained ventricular arrhythmias with amiodarone: prediction of efficacy with serial electrophysiologic studies. J Cardiovasc Pharmacol Therapeut1:123, 1996
18.
18. Venkatesh N, Somani P, Bersohn M, Phair HR, Kato R, Singh BN. Electropharamcology of amiodarone: absence of relationship to serum, myocardial and cardiac sarcolemmal membrane drug concentrations. Am Heart J112:916, 1986
19.
19. Antimisiaris M, Sarma JSM, Schoenbaum MP, Sharma PP, Venkataraman K, Singh BN.Effects of amiodarone on the circadian rhythm and power spectral changes of heart rate and QT interval: significance for the control of sudden cardiac death. Am Heart J128:884, 1994
20.
20. Charlier R. Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors. Br J Pharmacol39:668, 1970
21.
21. Singh BN, Venkatesh N, Nademanee K, Josephson MA, Kannan R. The historical development, cellular electrophysiology and clinical pharmacology of amiodarone. Prog Cardiovasc Dis31:249, 1989
22.
22. Mason JW, Hondeghem LM, Katzung BG. Block of inactivated sodium channels and of depolarization induced automaticity in guinea-pig papillary muscle by amiodarone. Circ Res55:277, 1984
23.
23. Singh BN. The coming of age of class III antiarrhythmic principle: retrospective and future trends. Am J Cardiol (in press)
24.
24. Singh BN. Advantages of beta-blockers versus antiarrhythmic drugs and calcium-channel antagonists in secondary prevention in survivors of myocardial infarction. Am J Cardiol66:9, 1990
25.
25. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with the prolongation of the QT interval and sudden death. Am Heart J54:59, 1957
26.
26. Singh BN, Hauswirth O. Comparative mechanisms of action of antiarrhythmic drugs. Am Heart J87:367, 1974
27.
27. Sager PT, Uppal P, Follmer CT, Antimisiaris M, Pruitt C, Singh BN. The frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation88:1063, 1993
28.
28. Papp J Gy, Nemeth M, Krassoki I, et al. Differential electrophysiologic effects of amiodarone in canine Purkinje fibers and ventricular muscle. J Cardiovasc Pharmacol Therapeut1:287, 1996
29.
29. Yabek S, Kato R, Singh BN. Acute electrophysiologic effects of amiodarone and desethylamiodarone in isolated cardiac muscle. J Cardiovasc Pharmacol8:197, 1985
30.
30. Aomine M. Multiple electrophysiological actions of amiodarone in guinea pig heart. Naunyn Schmiedeberg Arch Pharmacol338:589, 1988
31.
31. Scheinman MM. Levine JH. Cannom DS, Kopelman FT, Chilson DA, Platia EV, Wilber DJ, Kowey PR, for the Intravenous Amiodarone Multicenter Investigators Group. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation92:3264, 1995
32.
32. Kowey PR, Levine JH, Pacifica A, et al., for the Intravenous Amiodarone Multicenter Investigators Group. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent hemodynamically destabilizing ventricular tachycardia and fibrillation. Circulation92:3255, 1995
33.
33. Gallagher JD. Bianchi J, Gessman LJ.A comparison of the electrophysiologic effects of acute and chronic amiodarone administration of canine Purkinje fibers. J Cardiovasc Pharmacol13:723, 1989
34.
34. Han J, Moe GK. Non-uniform recovery of excitability in ventricular muscle. Circ Res14:44, 1964
35.
35. Antzelevitch C, Sicouri S, Litovsky S, Lukas A, et al. Heterogeneity within the ventricular wvall. Circ Res69:1427, 1991
36.
36. Takanaka C, Singh BN. Barium-induced non-driven action potentials as a model of triggered potentials from early afterdepolarization: significance of slow-channel activity and differing effects of quinidine and amiodarone. J Am Coll Cardiol15:213, 1990
37.
37. Nishimura M, Follmer CH, Singer DH. Amiodarone blocks calcium current in single guinea-pig ventricular myocytes. J Pharmacol Exp Ther251:650, 1989
38.
38. Varro A, Virag L, Papp J Gy. Comparison of the chronic and acute effects of amiodarone on the calcium and potassium currents in isolated rabbit cardiac myocytes. Br J Pharmacol117:1181, 1996
39.
39. Perkiomaki JS, Koistinen MJ, Yli-Mayry S, Huikuri HV. Dispersion of QT interval in patients with and without susceptibility to ventricular tachyarrhythmias after previous myocardial infarction. J Am Coll Cardiol26:174, 1995
40.
40. Hii JTY, Wyse DG, Gillis AM, Dugg HJ, Solylo MS, Mitchell BLB. Precordial QT interval dispersion as a marker of torsades de pointes: disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation86:1372, 1992
41.
41. Cui G, Sen L, Uppal P, Sager PT, Singh BN. Effects of amiodarone, sematilide and sotalol on QT dispersion. Am J Cardiol74:896, 1994
42.
42. Antzelevitch C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. J Am Coll Cardiol23:259, 1994
43.
43. Sicouri S, Moro S, Siri LN, Elizari M, et al. Chronic amiodarone delays ventricular repolarization and reduces transmural dispersion of repolarization in the caninc heart. Pace1:638, 1996
44.
44. Waldo AL, Camm JA, deRuyter H. et al., for the SWORD Investigators. Effect of d-sotalol on mortality in patients with ventricular dysfunction after recent and remote myocardial infarction. Lancet348:7, 1996
